Journal article from Science Direct:
www.sciencedirect.com
Breakdown of significant points:
----------
Highlights
•
First COVID-19 outpatient study based on risk stratification and early antiviral treatment at the beginning of the disease.
•
Low-dose hydroxychloroquine combined with zinc and azithromycin was an effective therapeutic approach against COVID-19.
•
Significantly reduced hospitalisation rates in the treatment group.
•
Reduced mortality rates in the treatment group.
----------
----------
The antiviral effects of HCQ are well documented [19]. It is also known that chloroquine, and probably HCQ, have zinc ionophore characteristics, increasing intracellular zinc concentrations [20]. Zinc itself is able to inhibit coronavirus RNA-dependent RNA polymerase (RdRp) activity [21]. It has been hypothesised that zinc may enhance the efficacy of HCQ in treating COVID-19 patients [22]. The first clinical trial results confirming this hypothesis were recently published as a preprint [23]. Nevertheless, many studies with HCQ as monotherapy or in combination with the antibiotic azithromycin have been inconclusive so far [13], [14], [15], [16]. In all of these studies, HCQ was used later than 5 days after the onset of symptoms when hospitalised patients most likely had already progressed to stage II or III of the disease [6]. Regardless of the established antiviral effects of zinc and that many COVID-19 patients are prone to zinc deficiency, dependent on co-morbidities and drug treatments [22], none of these studies were designed to include zinc supplementation as combination treatment.
----------
----------
Fig. 2. Hospitalisation. Treatment with triple therapy of zinc, low-dose hydroxychloroquine and azithromycin was associated with significantly fewer hospitalisations compared with untreated patients of the public reference data. χ2 (1, N = 518) = 14.17; * P < 0.001.
----------
----------
Fig. 3. All-cause deaths. Treatment with triple therapy of zinc, low-dose hydroxychloroquine and azithromycin was associated with numerically fewer all-cause deaths compared with untreated patients of the public reference data. n.s., not significant. χ2 (1, N = 518) = 1.98; P = 0.12.
----------
bUt HyDrOxYcHlOrOqUiNe DoN't WoRk... bEcAuSe dRuMpH iS bAd aNd OrAnGe MaN bAd. REEEEEE! WAAH! WAAH! WAAH!
COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study
The aim of this study was to describe the outcomes of patients with coronavirus disease 2019 (COVID-19) in the outpatient setting after early treatmen…
www.sciencedirect.com
Breakdown of significant points:
----------
Highlights
•
First COVID-19 outpatient study based on risk stratification and early antiviral treatment at the beginning of the disease.
•
Low-dose hydroxychloroquine combined with zinc and azithromycin was an effective therapeutic approach against COVID-19.
•
Significantly reduced hospitalisation rates in the treatment group.
•
Reduced mortality rates in the treatment group.
----------
----------
The antiviral effects of HCQ are well documented [19]. It is also known that chloroquine, and probably HCQ, have zinc ionophore characteristics, increasing intracellular zinc concentrations [20]. Zinc itself is able to inhibit coronavirus RNA-dependent RNA polymerase (RdRp) activity [21]. It has been hypothesised that zinc may enhance the efficacy of HCQ in treating COVID-19 patients [22]. The first clinical trial results confirming this hypothesis were recently published as a preprint [23]. Nevertheless, many studies with HCQ as monotherapy or in combination with the antibiotic azithromycin have been inconclusive so far [13], [14], [15], [16]. In all of these studies, HCQ was used later than 5 days after the onset of symptoms when hospitalised patients most likely had already progressed to stage II or III of the disease [6]. Regardless of the established antiviral effects of zinc and that many COVID-19 patients are prone to zinc deficiency, dependent on co-morbidities and drug treatments [22], none of these studies were designed to include zinc supplementation as combination treatment.
----------
----------
Fig. 2. Hospitalisation. Treatment with triple therapy of zinc, low-dose hydroxychloroquine and azithromycin was associated with significantly fewer hospitalisations compared with untreated patients of the public reference data. χ2 (1, N = 518) = 14.17; * P < 0.001.
----------
----------
Fig. 3. All-cause deaths. Treatment with triple therapy of zinc, low-dose hydroxychloroquine and azithromycin was associated with numerically fewer all-cause deaths compared with untreated patients of the public reference data. n.s., not significant. χ2 (1, N = 518) = 1.98; P = 0.12.
----------
bUt HyDrOxYcHlOrOqUiNe DoN't WoRk... bEcAuSe dRuMpH iS bAd aNd OrAnGe MaN bAd. REEEEEE! WAAH! WAAH! WAAH!
